Nutrineal

Nutrinia is a clinical-stage biotechnology company focused on developing specialized therapeutic solutions for rare gastrointestinal diseases in infants. The company's lead candidate, NTRA-2112, is a proprietary oral formulation of insulin designed to promote intestinal maturation and improve nutrient absorption in preterm infants with intestinal malabsorption. By targeting the local insulin receptors in the gut, Nutrinia aims to reduce the reliance on parenteral nutrition and accelerate the transition to full enteral feeding. The company operates with a focus on neonatal intensive care unit (NICU) patients, addressing significant unmet needs in pediatric gastroenterology.